These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 21802104)

  • 1. Synergistic activity profile of griffithsin in combination with tenofovir, maraviroc and enfuvirtide against HIV-1 clade C.
    Férir G; Palmer KE; Schols D
    Virology; 2011 Sep; 417(2):253-8. PubMed ID: 21802104
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient single tobamoviral vector-based bioproduction of broadly neutralizing anti-HIV-1 monoclonal antibody VRC01 in Nicotiana benthamiana plants and utility of VRC01 in combination microbicides.
    Hamorsky KT; Grooms-Williams TW; Husk AS; Bennett LJ; Palmer KE; Matoba N
    Antimicrob Agents Chemother; 2013 May; 57(5):2076-86. PubMed ID: 23403432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors.
    Li Z; Zhou N; Sun Y; Ray N; Lataillade M; Hanna GJ; Krystal M
    Antimicrob Agents Chemother; 2013 Sep; 57(9):4172-80. PubMed ID: 23774428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple combination of carbosilane dendrimers, tenofovir and maraviroc as potential microbicide to prevent HIV-1 sexual transmission.
    Sepúlveda-Crespo D; Sánchez-Rodríguez J; Serramía MJ; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
    Nanomedicine (Lond); 2015; 10(6):899-914. PubMed ID: 25867856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro Study on Synergistic Interactions Between Free and Encapsulated Q-Griffithsin and Antiretrovirals Against HIV-1 Infection.
    Minooei F; Fried JR; Fuqua JL; Palmer KE; Steinbach-Rankins JM
    Int J Nanomedicine; 2021; 16():1189-1206. PubMed ID: 33623382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel agents for the treatment of HIV-2 infection.
    Peterson K; Rowland-Jones S
    Antivir Ther; 2012; 17(3):435-8. PubMed ID: 22301192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro synergistic activity against CCR5-tropic HIV-1 with combinations of potential candidate microbicide molecules HHA, KRV2110 and enfuvirtide (T20).
    Jenabian MA; Saïdi H; Charpentier C; Van Herrewege Y; Son JC; Schols D; Balzarini J; Vanham G; Bélec L;
    J Antimicrob Chemother; 2009 Dec; 64(6):1192-5. PubMed ID: 19875507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maraviroc and other HIV-1 entry inhibitors exhibit a class-specific redistribution effect that results in increased extracellular viral load.
    Kramer VG; Schader SM; Oliveira M; Colby-Germinario SP; Donahue DA; Singhroy DN; Tressler R; Sloan RD; Wainberg MA
    Antimicrob Agents Chemother; 2012 Aug; 56(8):4154-60. PubMed ID: 22615275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergistic activity of carbosilane dendrimers in combination with maraviroc against HIV in vitro.
    Córdoba EV; Arnáiz E; De La Mata FJ; Gómez R; Leal M; Pion M; Muñoz-Fernández MA
    AIDS; 2013 Aug; 27(13):2053-8. PubMed ID: 23612005
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp.
    Mori T; O'Keefe BR; Sowder RC; Bringans S; Gardella R; Berg S; Cochran P; Turpin JA; Buckheit RW; McMahon JB; Boyd MR
    J Biol Chem; 2005 Mar; 280(10):9345-53. PubMed ID: 15613479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Griffithsin Retains Anti-HIV-1 Potency with Changes in gp120 Glycosylation and Complements Broadly Neutralizing Antibodies PGT121 and PGT126.
    Fischer K; Nguyen K; LiWang PJ
    Antimicrob Agents Chemother; 2019 Dec; 64(1):. PubMed ID: 31611356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component.
    O'Keefe BR; Vojdani F; Buffa V; Shattock RJ; Montefiori DC; Bakke J; Mirsalis J; d'Andrea AL; Hume SD; Bratcher B; Saucedo CJ; McMahon JB; Pogue GP; Palmer KE
    Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6099-104. PubMed ID: 19332801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV entry inhibitors: progress in development and application.
    Lai WH; Huang L; Chen CH
    Yao Xue Xue Bao; 2010 Feb; 45(2):131-40. PubMed ID: 21348414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent strategy to inhibit HIV-1 by binding both gp120 and gp41.
    Kagiampakis I; Gharibi A; Mankowski MK; Snyder BA; Ptak RG; Alatas K; LiWang PJ
    Antimicrob Agents Chemother; 2011 Jan; 55(1):264-75. PubMed ID: 20956603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide.
    Emau P; Tian B; O'keefe BR; Mori T; McMahon JB; Palmer KE; Jiang Y; Bekele G; Tsai CC
    J Med Primatol; 2007 Aug; 36(4-5):244-53. PubMed ID: 17669213
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad anti-HIV activity of the Oscillatoria agardhii agglutinin homologue lectin family.
    Férir G; Huskens D; Noppen S; Koharudin LM; Gronenborn AM; Schols D
    J Antimicrob Chemother; 2014 Oct; 69(10):2746-58. PubMed ID: 24970741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic in vitro anti-HIV type 1 activity of tenofovir with carbohydrate-binding agents (CBAs).
    Férir G; Vermeire K; Huskens D; Balzarini J; Van Damme EJ; Kehr JC; Dittmann E; Swanson MD; Markovitz DM; Schols D
    Antiviral Res; 2011 Jun; 90(3):200-4. PubMed ID: 21501631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Models for predicting effective HIV chemoprevention in women.
    Nicol MR; Emerson CW; Prince HM; Nelson JA; Fedoriw Y; Sykes C; Geller EJ; Patterson KB; Cohen MS; Kashuba AD
    J Acquir Immune Defic Syndr; 2015 Apr; 68(4):369-76. PubMed ID: 25501616
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of primary resistance to HIV entry inhibitors among brazilian patients failing reverse transcriptase/protease inhibitors treatment reveal high prevalence of maraviroc resistance-related mutations.
    Alencar CS; Nishiya AS; Ferreira S; Giret MT; Diaz RS; Sabino EC
    AIDS Res Hum Retroviruses; 2010 Dec; 26(12):1267-71. PubMed ID: 20977300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable interactions between enfuvirtide and 1-beta-D-2,6-diaminopurine dioxolane in vitro.
    Tremblay CL; Poulin DL; Hicks JL; Selliah S; Chamberland A; Giguel F; Kollmann CS; Chou TC; Dong H; Hirsch MS
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3644-6. PubMed ID: 14576137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.